Equibles does not estimate personal net worth.
Get an email with a short summary when Biocryst Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get BCRX alertsCharlie Gayer is recorded as CEO and Board Member at Biocryst Pharmaceuticals Inc (BCRX) since January 1, 2026. Biocryst Pharmaceuticals Inc reported in an 8-K filed July 31, 2025 that Charlie Gayer was appointed director, effective January 1, 2026. Biocryst Pharmaceuticals Inc reported in an 8-K filed July 31, 2025 that Charlie Gayer was appointed Chief Executive Officer, effective January 1, 2026. Biocryst Pharmaceuticals Inc reported in an 8-K filed July 31, 2025 that Charlie Gayer was appointed President, effective August 1, 2025. Charlie Gayer has spoken on 5 earnings calls and 2 other investor events across 1 company, most recently for Biocryst Pharmaceuticals Inc on November 4, 2026. Biocryst Pharmaceuticals Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Biocryst Pharmaceuticals Inc includes Charles Gayer (CEO and Board Member), Vincent J. Milano (Chairman and Board Member), Babar Ghias (CFO and Chief Accounting Officer) and 7 others.
“On July 27, 2025, the Board approved an increase in the size of the Board from nine to ten directors, effective January 1, 2026, and elected Mr. Gayer to fill the vacancy created by the enlargement of the Board, effective January 1, 2026.”
“On July 27, 2025, the Board appointed Charlie Gayer, age 54, as the Company’s President, effective August 1, 2025, and as the Company’s Chief Executive Officer, effective January 1, 2026.”
“The third quarter was significant for BioCryst as we continue to deliver strong execution during a time of strategic evolution. On the HAE front, new patient prescriptions for Orlodeo continued at the same high level that we have seen all year.”
“And before I start, I'll be making, obviously, some forward-looking statements. And those statements have risks, which you can learn about at our website.”
“During the second quarter, we continued to execute effectively on the commercial and development fronts. We completed the integration of Astrea Therapeutics, and we further increased our cash generation through growing revenue and discipline spending.”
“We've got a product, Orlodeo, in the market for HAE, a prophylactic therapy, that did $602 million in revenue last year. And that's partly because of the product itself.”
“2026 is off to a very good start for Biocrist, marked by strong execution on our commercial and development programs, the smooth integration of astrotherapeutics, and discipline management of our finances.”
2026-01-01–present
2026-01-01–present
Source not stated
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2026-01-01–present
